T-Cell Prolymphocytic Leukemia

Observed

→ investigated in trials for

Alemtuzumabmonoclonal_antibody

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cytarabinesmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ruxolitinibsmall molecule

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Venetoclaxsmall_molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carmustinesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Duvelisibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Melphalansmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Busulfansmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cladribinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ibrutinibsmall_molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Niraparibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Romidepsinother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

T-Cell Prolymphocytic Leukemia studied in …STUDIED_INderived10 of 24show all (up to 200)
→ studied in	NCT05010005Phase 1 · recruiting A Study of Ruxolitinib and Duvelisib in People With Lymphoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT07311746Phase 1/Phase 2 · recruiting Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05377827Phase 1 · suspended Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT06810778Phase 1/Phase 2 · recruiting Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05978141recruiting A Registry for People With T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT04771572Phase 1 · recruiting Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT07356245Phase 2 · recruiting Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT04496349Phase 2 · recruiting A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL · condition mapped ALIAS · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT02512497Phase 1 · completed Romidepsin Maintenance After Allogeneic Stem Cell Transplantation · condition mapped ALIAS · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05823571Phase 1 · active not recruiting Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →

T-Cell Prolymphocytic Leukemia studied in …STUDIED_INderived10 of 24show all (up to 200)

→ studied in

NCT05010005Phase 1 · recruiting

A Study of Ruxolitinib and Duvelisib in People With Lymphoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)

—

Observed

→ studied in

NCT07311746Phase 1/Phase 2 · recruiting

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)

—

Observed

→ studied in

NCT05377827Phase 1 · suspended

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)

—

Observed

→ studied in

NCT06810778Phase 1/Phase 2 · recruiting

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)

—

Observed

→ studied in

NCT05978141recruiting

A Registry for People With T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)

—

Observed

→ studied in

NCT04771572Phase 1 · recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)

—

Observed

→ studied in

NCT07356245Phase 2 · recruiting

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)

—

Observed

→ studied in

NCT04496349Phase 2 · recruiting

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL · condition mapped ALIAS · 24 trials mapped (9 active)

—

Observed

→ studied in

NCT02512497Phase 1 · completed

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation · condition mapped ALIAS · 24 trials mapped (9 active)

—

Observed